Skip to main content

Table 4 Mediation effect of glucose on the relationship between glucose metabolism–relevant SNPs and CRC risk, stratified by obesity status and obesity-related factors

From: Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women

SNP

Nearest gene

 

Favorable Energy Balance Group

Unfavorable Energy Balance Group

Direct effect

Indirect effect

Total effect

Direct effect

Indirect effect

Total effect

Effect allele/Other allele

CRC risk in relation to SNP through pathways other than glucose

CRC risk in relation to SNP through glucose

CRC risk in relation to SNP

CRC risk in relation to SNP through pathways other than glucose

CRC risk in relation to SNP through glucose

CRC risk in relation to SNP

 

HRa

95% CI

Effect sizea

95% CI

HRa

95% CI

HRa

95% CI

Effect sizea

95% CI

HRa

95% CI

BMIb

 rs4607517

GCK

G/A

0.79

(0.60–1.02)

0.02

(0.002–0.04)

0.80

(0.64–1.00)

1.00

(0.65–1.55)

0.001

(−0.01–0.01)

1.06

(0.75–1.51)

 rs174550

FADS1

T/C

1.15

(0.92–1.43)

−0.002

(−0.01–0.01)

1.05

(0.87–1.27)

1.40

(0.97–2.03)

<0.001

(−0.01–0.01)

1.37

(1.02–1.83)

 rs11605924

CRY2

C/A

0.89

(0.73–1.09)

−0.004

(−0.01–0.02)

0.82

(0.69–0.98)

1.32

(0.94–1.85)

<0.001

(−0.004–0.004)

1.07

(0.82–1.39)

Waistc

 rs560887

G6PC2

T/C

0.75

(0.58–0.99)

0.01

(−0.03–0.004)

0.88

(0.70–1.11)

1.00

(0.75–1.34)

0.01

(−0.04–0.02)

1.01

(0.80–1.27)

 rs174550

FADS1

T/C

1.17

(0.91–1.51)

−0.01

(−0.02–0.01)

1.03

(0.83–1.28)

1.23

(0.93–1.63)

0.01

(−0.01–0.02)

1.25

(1.00–1.57)

 rs11605924

CRY2

C/A

0.84

(0.67–1.06)

−0.01

(−0.01–0.02)

0.81

(0.66–0.99)

1.20

(0.92–1.56)

0.004

(−0.02–0.01)

0.97

(0.79–1.20)

w/h Ratiod

 rs10885122

ADRA2A

G/T

0.80

(0.59–1.07)

−0.002

(−0.01–0.01)

0.84

(0.64–1.08)

1.36

(0.81–2.30)

<0.001

(−0.003–0.003)

1.58

(1.01–2.48)

Physical activity levele

 rs4607517

GCK

G/A

0.73

(0.52–1.00)

0.01

(−0.01–0.04)

0.72

(0.55–0.95)

0.95

(0.70–1.31)

0.01

(−0.01–0.02)

0.99

(0.76–1.28)

Dietary fat intakef

 rs4607517

GCK

G/A

0.91

(0.71–1.17)

0.01

(−0.004–0.03)

0.94

(0.76–1.17)

0.57

(0.33–1.01)

−0.003

(−0.01–0.01)

0.66

(0.43–1.00)

 rs11558471

SLC30A8

A/G

1.07

(0.87–1.31)

−0.02

(−0.04–0.004)

0.95

(0.80–1.12)

1.60

(0.93–2.75)

−0.002

(−0.01–0.01)

1.60

(1.07–2.40)

  1. BMI body mass index, CI confidence interval, CRC colorectal cancer, HR hazard ratio, SNP single–nucleotide polymorphism, w/h ratio waist-to-hip ratio
  2. Note: Proportions explained by glucose for SNP–CRC risk association for rs4607517 (1.5%, 0.5%, and 3.3% among non-obese group [BMI < 30, MET ≥10, and <40% calories from fat, respectively]; N/A [> 100%], 3.3%, and 12.5% among obese-group [BMI ≥ 30, MET <10, and ≥40% calories from fat, respectively]), for rs174550 (N/A [> 100%] and N/A [> 100%] among non-obese group [BMI < 30 and waist ≤88 cm, respectively]; 9.9% and 10.3% among obese-group [BMI ≥ 30 and waist >88 cm, respectively]), for rs11605924 (8.5% and 3.7% among non-obese group [BMI < 30 and waist ≤88 cm, respectively]; N/A [> 100%] and N/A [> 100%] among obese-group [BMI ≥ 30 and waist >88 cm, respectively]), for rs560887 (14.7% in waist ≤88 cm; N/A [>100%] in waist >88 cm), for rs10885122 (4.7% in w/h ≤ 0.85; 37.7% in w/h > 0.85), and for rs11558471 (12.5% in <40% calories from fat; 0.9% in ≥40% calories from fat). Only SNPs having statistically significant results are included. Numbers in bold face are statistically significant
  3. aMultivariate regression was adjusted by covariates (age, education, family history of diabetes mellitus, family history of colorectal cancer, cardiovascular disease ever, hypertension ever, high cholesterol requiring pills ever, total Healthy Eating Index-2005 score, dietary alcohol and total sugars per day, smoking status, lifetime partner, depressive symptom, oral contraceptive use, history of hysterectomy or oophorectomy, age at menarche, age at menopause, pregnancy history, breastfeeding at least 1 month, and hormone therapy); effect-modifier variables (physical activity, BMI, and w/h ratio), when not evaluated as effect modifier variables, were adjusted as a covariate; when stratified via waist circumference, w/h ratio was not adjusted
  4. bParticipants stratified by BMI as non-obese (BMI < 30, n = 3675) or obese (BMI ≥ 30, n = 1704); interaction tests presented for the effect of BMI on the association between CRC and rs4607517 (effect size −0.30, p-value 0.65), rs174550 (effect size −0.70, p-value 0.09), and rs11605924 (effect size −0.38, p-value 0.15)
  5. cParticipants stratified by waist circumference as non-obese (waist ≤88 cm; n = 3042) or obese (waist >88 cm; n = 2337); interaction tests presented for the effect of waist circumference on the association between CRC and rs560887 (effect size −0.40, p-value 0.27), rs174550 (effect size −0.89, p-value 0.01), and rs11605924 (effect size −0.42, p-value 0.09)
  6. dParticipants stratified by w/h as non-obese (w/h ≤ 0.85; n = 3712) or obese (w/h > 0.85; n = 1667); interaction test presented for the effect of w/h on the association between CRC and rs10885122 (effect size 0.59, p-value 0.02)
  7. eParticipants stratified by physical activity level as non-obese (MET ≥10; n = 2344) or obese (MET <10; n = 3035); interaction test presented for the effect of physical activity on the association between CRC and rs4607517 (effect size 0.94, p-value 0.14)
  8. fParticipants stratified by dietary fat intake as non-obese (< 40% calories from fat; n = 4325) or obese (≥ 40% calories from fat; n = 1054); interaction tests presented for the effect of dietary fat intake on the association between CRC and rs4607517 (effect size 1.45, p-value 0.01) and rs11558471 (effect size −1.53, p-value 0.04)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us